L04AB04 • adalimumab • Antineoplastic and immunomodulating agents | Immunosuppressants | Tumor necrosis factor alpha (tnf-alpha) inhibitors
Adalimumab is a biologic medication used to treat autoimmune inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. It works by inhibiting tumor necrosis factor-alpha (TNF-α), a protein involved in inflammation.
It is administered as subcutaneous injections, usually once every two weeks, depending on the medical indication. Adalimumab helps reduce inflammation, alleviate symptoms, and prevent joint damage.
Side effects may include injection site reactions, respiratory infections, headaches, or nausea. In rare cases, it may increase the risk of severe infections or certain types of cancer.
Patients should be regularly monitored by their doctor and report any signs of infection or other health issues. It is contraindicated in cases of active severe infections.
Substance: adalimumab
Date of last drug list: 01-07-2020
Commercial code: W59945002
Concentration: 40mg / 0.8ml
Pharmaceutical form: injectible solution
Quantity: 2
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).